Synthesis and optimization of 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one based inhibitors of human neutrophil elastase

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4743-4746

  Shreder, Kevin R ^a   Cajica, Julia ^a   Du, Lingling ^a   Fraser, Allister ^a   Hu, Yi ^a   Kohno, Yasushi ^b   Lin, Emme C K ^a   Liu, Steve J ^a   Okerberg, Eric ^a   Pham, Lan ^a   Wu, Jiangyue ^a   Kozarich, John W ^a  

^a ACTIVX BIOSCIENCES INC   (United States)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Benzoxazinone; Human neutrophil elastase; Hydrolytic stability; Inhibitor; Plasma stability

Indexed keywords

2 [2 (4 METHYLPIPERAZIN 1 YL)PYRIDIN 3 YL] DERIVATIVE; 5 ETHYL 7 METHOXYBENZ[D][1,3]OXAZIN 4 ONE; 5 METHYL 2 (2 PHENOXYPYRIDIN 3 YL)BENZ[D][1,3]OXAZIN 4 ONE; BENZOXAZINE DERIVATIVE; LEUKOCYTE ELASTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BENZOXAZINES; HALF-LIFE; HUMANS; LEUKOCYTE ELASTASE; RATS; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 67651102823     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.053     Document Type: Article

References (21)

1. Travis J. Am. J. Med. 84 (1988) 37
2. Owen C.A., and Campbell E.J. Semin. Cell Biol. 6 (1995) 367
3. Moraes T.J., Chow C.W., and Downey G.P. Crit. Care Med. 31 (2003) 189
4. Wang Z., Chen F., Zhai R., Zhang L., Su L., Lin X., Thompson T., and Christiani D.C. PLoS ONE 4 (2009) e4380
5. Int. J. Tuberc. Lung Dis. 12 (2008) 361
6. Colson E., Wallach J., and Hauteville M. Biochimie 87 (2005) 223
7. Arcadi A., Asti C., Brandolini L., Caselli G., Marinelli F., and Ruggieri V. Bioorg. Med. Chem. Lett. 9 (1999) 1291
8. Uejima Y., Oshida J., Kawabata H., Kokubo M., Kato Y., and Fujii K. Biochem. Pharmacol. 48 (1994) 426
9. Krantz A., Spencer R.W., Tam T.F., Liak T.J., Copp L.J., Thomas E.M., and Rafferty S.P. J. Med. Chem. 33 (1990) 464
10. Radhakrishnan R., Presta L.G., Meyer Jr. E.F., and Wildonger R. J. Mol. Biol. 198 (1987) 417
11. Gütschow M., and Neumann U. J. Med. Chem. 41 (1998) 1729
12. Gütschow M., Kuerschner L., Neumann U., Pietsch M., Löser R., Koglin N., and Eger K. J. Med. Chem. 42 (1999) 5437
13. Metz W.A., and Peet N.P. In: Kahn M. (Ed). Elastase Inhibitors in High Throughput Screening for Novel Anti-Inflammatories (2000), Birkhäuser Verlag Basel, Switzerland 49
14. Ohbayashi H. Exp. Opin. Ther. Pat. 12 (2002) 65
15. Ohbayashi H. IDrugs 5 (2002) 910
16. 50 values.
17. Hey D.H., and Lobo L.C. J. Org. Chem. 17 (1952) 164
18. 4-Hydroxy-2-pyrones were readily prepared using a modification of the Katritzky method in which 2,2,6-trimethyl-1,3-dioxin-4-one was acylated using short chain alkyl or cycloalkyl acid chlorides. Subsequent O-methylation with dimethylsulfate yielded the 4-methoxy-pyrones. See:. Katritzky A.R., Wang Z., Wang M., Hall C.D., and Suzuki K. J. Org. Chem. 70 (2005) 4854
19. Deshpande V.H., Khan R.A., and Ayyanagar N.R. Indian J. Chem. 35B (1996) 790
20. Alkaline hydrolysis rates were measured by the disappearance of the characteristic absorbance maximum for the intact benzoxazinone ring (340 nm ± 10 nm) in 200 mM, pH 9.2 sodium borate and 1% DMSO. Hydrolysis rates were determined through linear regression analysis of the progress curves and then converted to half-life data. See:. Stein R.L., Strimpler A.M., Viscarello B.R., Wildonger R.A., Mauger R.C., and Trainor D.A. Biochemistry 26 (1987) 4126
21. Test compounds (2 μM) were incubated in heparin treated rat plasma at 37 °C. Following precipitation of the plasma proteins with acetonitrile, the concentration of test compound was quantified against an internal standard using ESI-MS. Half-life data was calculated from a fit of compound concentration versus time to a first order rate constant.